Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500947 | 1.00 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL5946675 | 1.00 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL8656868 | 0.98 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL9762807 | 0.94 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL113955 | 0.88 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL5946928 | 0.85 | CASP3 (0.46) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL22926235 | 0.84 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2443034 | 0.84 | CASP3 (0.51) | RAB9ANPC1SMN1; SMN2TLR8CASP3 | |
| SCHEMBL11335376 | 0.82 | APP (0.63) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10383965 | 0.82 | CASP3 (0.45) | RAB9ANPC1SMN1; SMN2TLR8CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-01-04 | — | — | US | disclosed |
| US-9798057-B2 | Composition for polarization film, polarization film, and display device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2364089-B1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140339482-A1 | COMPOSITION FOR POLARIZATION FILM, POLARIZATION FILM, AND DISPLAY DEVICE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2014-11-20 | — | — | US | disclosed |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2014-04-10 | — | — | US | disclosed |
| US-8349849-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2364089-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010051031-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-0498277-B1 | Optically active benzthiazoles, liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KK (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5194177-A | Trifluoromethylalkyl ethers of benzothiazolebenzyl compounds | CANON KABUSHIKI KAISHA (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0498277-A1 | Optically active benzthiazoles, liquid crystal composition, liquid crystal device, display apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | RAB9A 2500/4885NPC1 592/4885SMN1; SMN2 1771/4885 |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | RAB9A 2500/4885NPC1 592/4885SMN1; SMN2 1771/4885 |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | RAB9A 2500/4885NPC1 592/4885SMN1; SMN2 1771/4885 |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | RAB9A 2500/4885NPC1 592/4885SMN1; SMN2 1771/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | RAB9A 2500/4885NPC1 592/4885SMN1; SMN2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.